To the Cystic Fibrosis Community
On 5th November 2016, the PBAC will meet to decide whether KALYDECO is approved for reimbursement for 2-5 year old children in Australia.
This label extension will greatly benefit 30 little Australians. The KALYDECO KIWI study resulted in a drop in sweat chloride and most importantly, little lungs were kept healthier for longer.
CFA is asking the cystic fibrosis community to support the approval of KALYDECO for 2-5 year olds by going to the PBAC website and complete a consumer comment. Comments will not be accepted after 5pm (AEST) on 5 October 2016.
The key points that need to be made are:
- There is nothing like Kalydeco … it is a drug that treats the disease, not the symptoms.
- Kalydeco slows down lung damage resulting in better health outcomes across a child’s life.
- Overseas studies show 50 mmol/litre reduction in sweat chloride.
- Every day of delay, young lungs are experiencing irreparable damage.
200 Australians over the age of 6 years are currently are benefiting from KALYDECO. Let’s expand it by 30 people and support little Australian between the ages of 2-5 year.
Please call or email CFA if you have any questions or if you would like to help further create a My Story video and send it to email@example.com.
You can view some wonderful creative films on our website.
All My Story videos will be used to make our case with the PBAC.
Cystic Fibrosis Australia